Literature DB >> 8956457

Unique tumor antigens redefined as mutant tumor-specific antigens.

D Mumberg1, M Wick, H Schreiber.   

Abstract

The extraordinary specificity of immune responses mediated by T cells against individual syngeneic tumors has led to the concept that many tumor antigens are 'unique'. The recent isolation of several T-cell-recognized unique antigens from various murine and human tumors has shown that the antigenic peptides are caused by somatic mutations and, thus, are truly tumor-specific. The following review summarizes current knowledge about these mutant tumor-specific antigens and their possible role in the development and progression of cancer. It also discusses some functional differences between mutant tumor-specific and shared tumor antigens, which generally represent unaltered peptides, also present on some normal cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8956457     DOI: 10.1006/smim.1996.0037

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  15 in total

Review 1.  "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.

Authors:  Matthew R Buckwalter; Pramod K Srivastava
Journal:  Semin Immunol       Date:  2008-08-20       Impact factor: 11.130

Review 2.  Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.

Authors:  Bernhard Frankenberger; Sybille Regn; Christiane Geiger; Elfriede Noessner; Christine S Falk; Heike Pohla; Miran Javorovic; Tobias Silberzahn; Susanne Wilde; Alexander Buchner; Michael Siebels; Ralph Oberneder; Gerald Willimsky; Antonio Pezzutto; Thomas Blankenstein; Dolores J Schendel
Journal:  World J Urol       Date:  2005-07-05       Impact factor: 4.226

Review 3.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity.

Authors:  Ussama M Abdel-Motal; Kim Wigglesworth; Uri Galili
Journal:  Cancer Immunol Immunother       Date:  2009-01-28       Impact factor: 6.968

Review 5.  Specificity in cancer immunotherapy.

Authors:  Andrea Schietinger; Mary Philip; Hans Schreiber
Journal:  Semin Immunol       Date:  2008-08-05       Impact factor: 11.130

6.  Tumor-specific immune responses.

Authors:  Hans Schreiber
Journal:  Semin Immunol       Date:  2008-11-01       Impact factor: 11.130

Review 7.  Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits.

Authors:  Uri Galili
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

8.  A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.

Authors:  Osama E Rahma; Ed Ashtar; Ramy Ibrahim; Antoun Toubaji; Barry Gause; Vincent E Herrin; W Marston Linehan; Seth M Steinberg; Frank Grollman; George Grimes; Sarah A Bernstein; Jay A Berzofsky; Samir N Khleif
Journal:  J Transl Med       Date:  2010-01-28       Impact factor: 5.531

9.  Trial watch: Peptide vaccines in cancer therapy.

Authors:  Erika Vacchelli; Isabelle Martins; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

10.  In situ conversion of tumors into autologous tumor-associated antigen vaccines by intratumoral injection of α-gal glycolipids.

Authors:  Uri Galili
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.